Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers

Next Previous
Trial Profile

A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SPR 741 (Primary) ; Aztreonam; Ceftazidime; Tazobactam
  • Indications Gram-negative infections
  • Focus Pharmacokinetics
  • Sponsors Spero Therapeutics

Most Recent Events

  • 01 Jul 2019 Results from SPR741-101s and SPR741-102 studies were published in the Antimicrobial Agents and Chemotherapy.
  • 28 Aug 2018 According to a Spero Therapeutics media release, the company expects that data from a phase 1 clinical trial of SPR206 (298950) together with the data from this completed trial (SPR741) will enable the selection of a lead candidate from the Potentiator Platform to move forward into late stage development.
  • 23 May 2018 Results presented in a Spero Therapeutics media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top